Quimatryx licenses cancer compound for $92 million.

Fuente: El Diario Vasco, 4/4/2022

Quimatryx has been selected by Cancer Innova to develop new oral inhibitors for the treatment of glioblastoma.

Fuente: El español, 28/01/2022 

HDAC6 Inhibitor QTX125 Slows Mantle Cell Lymphoma Progression, Preclinical Study Shows

Jun 21, 2018, Lymphoma News Today (USA)

https://lymphomanewstoday.com/2018/06/21/qtx125-slows-mantle-cell-lymphoma-progression-mouse-study/

New epigenetic drug against Mantle Cell Lymphoma

Jun 13, 2018, Drug Target Review (UK)
A new study presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL)…

https://www.drugtargetreview.com/news/32438/epigenetic-drug-mantle-cell-lymphoma/